NordMedica A/S has been acquired by Eurocept B.V.
March 2013 — The Dutch pharmaceutical company Eurocept B.V. has acquired 100% of the share capital in the Danish specialty pharmaceutical company NordMedica A/S for an undisclosed consideration.
NordMedica A/S was founded in 2003 as a privately held specialty pharmaceutical company focused on the commercialization and marketing of niche pharmaceutical products. The company holds the rights to an oncology product under the brand names Amekrin®, Amsidine® and Amsidyl® in more than 25 countries. The product is based on a chemotherapy drug for the treatment of Acute Myeloid Leukemia (AML) and Acute Lymphatic Leukemia (ALL). All other assets and liabilities together with all employees were transferred to NordMedica International before the transaction.
Eurocept is a rapidly growing company active in the pharmaceutical and homecare market in the Benelux countries. Eurocept offers products and services that answer to pharmaceutical, technological and nursing needs in medical care as well as a unique combination of medical technology and distribution in the therapeutic areas of anesthesia, oncology, pediatrics, psychiatry, immunology, ADHD and urology.
Our role in the transaction
Oaklins' team in Denmark acted as financial and strategic advisor to the seller in this transaction.
Talk to the deal team
Related deals
Life & Mobility has attracted investor Bolster Investment Partners
Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.
Learn moreAsana Gruppe has sold selected outpatient service areas to Luzerner Kantonsspital
Luzerner Kantonsspital (LUKS) has acquired key parts of Asana Spital Menziken AG’s outpatient services from Asana Gruppe AG, including its ambulance service, primary care practice and ambulatory care center. The transaction supports the long-term continuity of local medical care in the Swiss Wynen and Seetal regions and ensures these services remain available close to patients’ homes.
Learn moreLaboratoires Herbolistique has received a majority investment from Yotta Capital Partners and co-investors
Laboratoires Herbolistique has received a majority investment from Yotta Capital Partners alongside co-investors Ouest Croissance, Sodero and CE IDF, with Bpifrance, Océans Participations and the management team reinvesting.
Learn more